Source: Proactive Investors

Lipozene: Lipocine's LPCN 1111 Phase 2b clinical study kicks off

The first patient has been dosed in Lipocene's Phase 2b clinical study for LPCN 1111, its novel testosterone replacement therapy product candidate.

Read full article »
Lipozene's Competitors | Lipozene's News | Lipozene's Financials
Stay up-to-date with the latest news on Lipozene
Est. Annual Revenue
$25-100M
Est. Employees
100-250
CEO Avatar

CEO

Thomas Barker

CEO Approval Rating

70/100

Read more
Stay up-to-date with the latest news on Lipozene